Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD

Chronic lung disease: ‘Triple’ therapy could prove beneficial A dual bronchodilator therapy taken together with corticosteroid inhalers may benefit patients with severe chronic lung disease. Bronchodilator drugs relax the lungs and widen airways in patients with chronic obstructive pulmonary disease...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anthony D’Urzo, Dave Singh, Esther Garcia Gil
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/654a3cf29b0b4a31be51af762d98abe5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:654a3cf29b0b4a31be51af762d98abe5
record_format	dspace
spelling	oai:doaj.org-article:654a3cf29b0b4a31be51af762d98abe52021-12-02T11:51:10ZUse of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD10.1038/s41533-016-0009-32055-1010https://doaj.org/article/654a3cf29b0b4a31be51af762d98abe52017-02-01T00:00:00Zhttps://doi.org/10.1038/s41533-016-0009-3https://doaj.org/toc/2055-1010Chronic lung disease: ‘Triple’ therapy could prove beneficial A dual bronchodilator therapy taken together with corticosteroid inhalers may benefit patients with severe chronic lung disease. Bronchodilator drugs relax the lungs and widen airways in patients with chronic obstructive pulmonary disease (COPD). While recent studies have shown that a dual bronchodilator therapy containing aclidinium and formoterol significantly improves lung function in COPD, little is known about combining the dual therapy with inhaled corticosteroids (ICSs). Anthony D’Urzo at the University of Toronto, Canada, and co-workers analysed data from 3394 patients with COPD undergoing dual therapy trials. Of these, 1180 were already taking ICSs. The team compared symptoms in the ICS group with those not taking ICSs. The dual therapy improved lung function across both groups regardless of ICS use, though patients gained different clinical benefits depending on ICS use and disease severity.Anthony D’UrzoDave SinghEsther Garcia GilNature PortfolioarticleDiseases of the respiratory systemRC705-779ENnpj Primary Care Respiratory Medicine, Vol 27, Iss 1, Pp 1-5 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the respiratory system RC705-779
spellingShingle	Diseases of the respiratory system RC705-779 Anthony D’Urzo Dave Singh Esther Garcia Gil Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
description	Chronic lung disease: ‘Triple’ therapy could prove beneficial A dual bronchodilator therapy taken together with corticosteroid inhalers may benefit patients with severe chronic lung disease. Bronchodilator drugs relax the lungs and widen airways in patients with chronic obstructive pulmonary disease (COPD). While recent studies have shown that a dual bronchodilator therapy containing aclidinium and formoterol significantly improves lung function in COPD, little is known about combining the dual therapy with inhaled corticosteroids (ICSs). Anthony D’Urzo at the University of Toronto, Canada, and co-workers analysed data from 3394 patients with COPD undergoing dual therapy trials. Of these, 1180 were already taking ICSs. The team compared symptoms in the ICS group with those not taking ICSs. The dual therapy improved lung function across both groups regardless of ICS use, though patients gained different clinical benefits depending on ICS use and disease severity.
format	article
author	Anthony D’Urzo Dave Singh Esther Garcia Gil
author_facet	Anthony D’Urzo Dave Singh Esther Garcia Gil
author_sort	Anthony D’Urzo
title	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
title_short	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
title_full	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
title_fullStr	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
title_full_unstemmed	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
title_sort	use of concomitant inhaled corticosteroids: pooled data from two phase iii studies of aclidinium plus formoterol in copd
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/654a3cf29b0b4a31be51af762d98abe5
work_keys_str_mv	AT anthonydurzo useofconcomitantinhaledcorticosteroidspooleddatafromtwophaseiiistudiesofaclidiniumplusformoterolincopd AT davesingh useofconcomitantinhaledcorticosteroidspooleddatafromtwophaseiiistudiesofaclidiniumplusformoterolincopd AT esthergarciagil useofconcomitantinhaledcorticosteroidspooleddatafromtwophaseiiistudiesofaclidiniumplusformoterolincopd
_version_	1718395168135053312

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD

Ejemplares similares